11.2 kg Average Loss With Tirzepatide vs. 5.7 kg With Semaglutide
SURPASS-2 compared tirzepatide with semaglutide 1 mg in adults taking metformin for type 2 diabetes, with 40-week glucose and weight results.
At week 40, mean HbA1c change was −2.01, −2.24, and −2.30 percentage points with tirzepatide 5 mg, 10 mg, and 15 mg, versus −1.86 with semaglutide 1 mg.
1,879 adults with type 2 diabetes inadequately controlled on metformin monotherapy, with baseline HbA1c from 7.0% to 10.5%; 40-week treatment period plus 4-week safety follow-up. Read the linked peer-reviewed source for the full methodology, findings, and limitations.